Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities

C Hu, J Yang, Z Qi, H Wu, B Wang, F Zou, H Mei… - MedComm, 2022 - Wiley Online Library
The heat shock proteins (HSPs) are ubiquitous and conserved protein families in both
prokaryotic and eukaryotic organisms, and they maintain cellular proteostasis and protect …

[HTML][HTML] Genomic instability, inflammatory signaling and response to cancer immunotherapy

M Chen, R Linstra, MATM van Vugt - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Genomic and chromosomal instability are hallmarks of cancer and shape the genomic
composition of cancer cells, thereby determining their behavior and response to treatment …

Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors

K Ludford, WJ Ho, JV Thomas, KPS Raghav… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …

Survival improvement for patients with metastatic colorectal cancer over twenty years

FA Zeineddine, MA Zeineddine, A Yousef, Y Gu… - NPJ Precision …, 2023 - nature.com
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC),
the median overall survival of both control and experimental arms has steadily improved …

[HTML][HTML] N6-methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer

S Wang, S Gao, Y Zeng, L Zhu, Y Mo, CC Wong, Y Bao… - Gastroenterology, 2022 - Elsevier
Background & Aims N6-methyladenosine (m 6 A) governs the fate of RNAs through m 6 A
readers. Colorectal cancer (CRC) exhibits aberrant m 6 A modifications and expression of m …

Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update

AE Boukouris, M Theochari, D Stefanou… - Critical reviews in …, 2022 - Elsevier
The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …

Biomarkers in colorectal cancer: the role of translational proteomics research

BA Alves Martins, GF de Bulhoes, IN Cavalcanti… - Frontiers in …, 2019 - frontiersin.org
Colorectal cancer is one of the most common cancers in the world, and it is one of the
leading causes of cancer-related death. Despite recent progress in the development of …

[HTML][HTML] Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

DT Le, LA Diaz Jr, TW Kim, E Van Cutsem… - European Journal of …, 2023 - Elsevier
Background Pembrolizumab demonstrated durable clinical benefit and manageable safety
in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch …

[HTML][HTML] Biomarkers in colorectal cancer: the role of translational proteomics research

BAA Martins, GF De Bulhões, IN Cavalcanti… - Frontiers in …, 2019 - ncbi.nlm.nih.gov
Colorectal cancer is one of the most common cancers in the world, and it is one of the
leading causes of cancer-related death. Despite recent progress in the development of …

Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability–high/mismatch …

A Hollebecque, HC Chung, MJ De Miguel… - Clinical Cancer …, 2021 - AACR
Purpose: Immune checkpoint inhibitors show high response rates and durable clinical
benefit in microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) tumors …